CHOP (cyclophosphamide [CPA], vincristine [VCR], doxorubicin [DXR], and prednisolone) combined with rituximab (R‐CHOP), the first anti‐CD20 monoclonal antibody, is the standard treatment for untreated DLBCL [4, 5, 6]. The gene discussed is DDIT3; the disease is diffuse large B-cell lymphoma.